Search results
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoEHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association ...
...Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European ...
Morningstar· 6 days agoNEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE ...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 7 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress PR Newswire HOUSTON ...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
WTNH-TV New Haven· 6 days ago(ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B have been accepted for an oral presentation and poster presentation at the 2024 ...
BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in...
Digital Journal· 6 days agoFirst data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients.Further updates from the IV arm; a fifth CR has been observed, ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoMP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into
Q1 2024 Omeros Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoResults from the combination stage of the Phase 2 switch-over trial have been selected for a podium presentation at the Annual Congress of the European Hematology ...
Aptose Reports Results for the First Quarter 2024
Digital Journal· 6 days agoTUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed ...
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress - Innate Pharma (NASDAQ:IPHA)
Benzinga· 6 days agoTwo abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate's
